이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dynavax Technologies 관리

관리 기준 확인 3/4

Dynavax Technologies' CEO는 Ryan Spencer, Dec2019 에 임명되었습니다 의 임기는 4.5 년입니다. 총 연간 보상은 $ 5.81M, 13.1% 로 구성됩니다. 13.1% 급여 및 86.9% 보너스(회사 주식 및 옵션 포함). 는 € 2.41M 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 2.41M. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 6 년입니다.

주요 정보

Ryan Spencer

최고 경영자

US$5.8m

총 보상

CEO 급여 비율	13.1%
CEO 임기	4.6yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	6.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ryan Spencer 의 보수는 Dynavax Technologies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$9m
Dec 31 2023	US$6m	US$760k	-US$6m
Sep 30 2023	n/a	n/a	US$61m
Jun 30 2023	n/a	n/a	US$111m
Mar 31 2023	n/a	n/a	US$236m
Dec 31 2022	US$6m	US$695k	US$293m
Sep 30 2022	n/a	n/a	US$320m
Jun 30 2022	n/a	n/a	US$228m
Mar 31 2022	n/a	n/a	US$104m
Dec 31 2021	US$5m	US$600k	US$72m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$62m
Dec 31 2020	US$2m	US$515k	-US$75m
Sep 30 2020	n/a	n/a	-US$97m
Jun 30 2020	n/a	n/a	-US$138m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$3m	US$391k	-US$156m

보상 대 시장: Ryan 의 총 보상 ($USD 5.81M )은 German 시장( $USD 1.53M ).

보상과 수익: Ryan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ryan Spencer (46 yo)

4.6yrs

테뉴어

US$5,810,736

보상

Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as Interim Chief Financial Officer of Dynavax Technologies Corporation since March 29, 2024. He s...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ryan Spencer	CEO, Interim CFO & Director	4.6yrs	US$5.81m	0.18% $ 2.3m
David Novack	President & COO	11.3yrs	US$2.99m	0.024% $ 325.4k
Robert Janssen	Chief Medical Officer and Senior VP of Clinical Development	11yrs	US$1.88m	0.049% $ 654.8k
Kelly MacDonald	Senior VP & CFO (Leave of Absence)	less than a year	US$2.07m	0.0059% $ 78.4k
Justin Burgess	Chief Accounting Officer & Controller	4.2yrs	데이터 없음	데이터 없음
Jeff Coon	Senior VP & Chief Human Resources Officer	5.5yrs	데이터 없음	데이터 없음
Paul Cox	VP of Investor Relations & Corporate Communications	1.5yrs	데이터 없음	데이터 없음
John Slebir	Senior VP & General Counsel	3.1yrs	데이터 없음	데이터 없음
Donn Casale	Senior VP & Chief Commercial Officer	no data	데이터 없음	데이터 없음
Dong Yu	Senior Vice President of Vaccine Research	3.4yrs	데이터 없음	데이터 없음
Eric Frings	VP, Site Head & MD for Dynavax GmbH	3.5yrs	데이터 없음	데이터 없음
Todd Lopeman	Senior Vice President of Technical Operations	3.5yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 관리: DYF1 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ryan Spencer	CEO, Interim CFO & Director	4.6yrs	US$5.81m	0.18% $ 2.3m
Peggy Phillips	Independent Director	17.9yrs	US$298.73k	0.021% $ 282.7k
Daniel Kisner	Independent Director	14yrs	US$290.73k	0.0011% $ 15.3k
Francis Cano	Independent Director	14.7yrs	US$278.73k	0.016% $ 212.4k
Robert Coffman	Member of Scientific Advisory Board	1.5yrs	US$1.83m	데이터 없음
Drew Pardoll	Member of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음
Julie Eastland	Independent Director	4yrs	US$293.73k	0% $ 0
Stanley Plotkin	Member of Scientific Advisory Board	6.1yrs	US$20.00k	데이터 없음
Scott Myers	Independent Chairman of the Board	2.8yrs	US$323.73k	0% $ 0
Miriam Merad	Member of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음
Laura Q. Chow	Member of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음
E. Wherry	Member of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

73.5yo

평균 연령

경험이 풍부한 이사회: DYF1 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.

Dynavax Technologies 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

President & COO recently sold €174k worth of stock

President & COO recently sold €646k worth of stock

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022

High number of new directors

Dong Yu Joins in Dynavax Technologies Corporation as Senior Vice President of Vaccine Research and A Member of the Executive Team

Recent updates

Dynavax Technologies Corporation Initiates Phase 1/2 Study of Novel Shingles Vaccine Program

Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.19 loss in 1Q 2023)

Dynavax Technologies Corporation to Report Q1, 2024 Results on May 08, 2024

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.05 loss per share (vs US$2.32 profit in FY 2022)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Dynavax Technologies Corporation to Report Q4, 2023 Results on Feb 22, 2024

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.50 in 3Q 2022)

Dynavax Technologies Corporation to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.027 (vs US$1.02 in 2Q 2022)

Dynavax Technologies Corporation to Report Q2, 2023 Results on Aug 03, 2023

President & COO recently sold €174k worth of stock

Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.26 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$2.32 (vs US$0.62 in FY 2021)

Dynavax Technologies Corporation to Report Q4, 2022 Results on Feb 23, 2023

President & COO recently sold €646k worth of stock

Third quarter 2022 earnings released: EPS: US$0.50 (vs US$0.24 loss in 3Q 2021)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Dynavax Technologies Corporation Announces First Participant Dosed in A Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$1.02 (vs US$0.039 in 2Q 2021)

Dynavax Technologies Corporation Revises Earnings Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q2, 2022 Results on Aug 04, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Dynavax Technologies Corporation Reaffirms Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.26 (vs US$0.007 in 1Q 2021)

Dynavax Technologies Corporation to Report Q1, 2022 Results on May 05, 2022

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dynavax Technologies Corporation Provides Revenue Guidance for the Full Year 2022

Dynavax Technologies Corporation to Report Q4, 2021 Results on Feb 28, 2022

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.04 profit in 3Q 2020)

Forecast to breakeven in 2021

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

Second quarter 2021 earnings released: EPS US$0.039 (vs US$0.53 loss in 2Q 2020)

High number of new directors

Dynavax Technologies Corporation(NasdaqCM:DVAX) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: EPS US$0.008 (vs US$0.15 loss in 1Q 2020)

Full year 2020 earnings released: US$0.75 loss per share (vs US$2.16 loss in FY 2019)

Revenue beats expectations

Dynavax Technologies Corporation Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine

Dynavax Technologies Corporation to Report Q4, 2020 Results on Feb 25, 2021

Dong Yu Joins in Dynavax Technologies Corporation as Senior Vice President of Vaccine Research and A Member of the Executive Team

Dynavax Technologies Corporation and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018

Dynavax Technologies Corporation Enters into an Agreement with the Coalition for Epidemic Preparedness Innovations

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

New 90-day high: €5.08

Dynavax Technologies Corporation Appoints Kelly Macdonald as Its Senior Vice President and Principal Financial Officer, Effective March 1, 2021

Dynavax Technologies Corporation Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Serum Institute of India Partneres with Dynavax Technologies Corporation Jointly Announces First Participants Dosed in the Phase 1/2 Clinical Trial for a Covid-19 Vaccine

European CHMP Adopts Positive Opinion for HEPLISAV-B®, Dynavax's Two Dose Adult Hepatitis B Adjuvanted Vaccine

Third quarter 2020 earnings released: EPS US$0.04

Revenue beats expectations

New 90-day low: €3.16

New 90-day low: €3.50

Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

Dynavax Technologies Corporation Announces Management Changes